Scarica l'app Stockscreener
255.25
0.79%
2.00
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$253.25
Aprire:
$255.11
Volume 24 ore:
220.57K
Relative Volume:
0.98
Capitalizzazione di mercato:
$5.12B
Reddito:
$274.48M
Utile/perdita netta:
$153.56M
Rapporto P/E:
34.61
EPS:
7.3755
Flusso di cassa netto:
$114.06M
1 W Prestazione:
+4.92%
1M Prestazione:
+19.72%
6M Prestazione:
+32.51%
1 anno Prestazione:
+121.94%
Intervallo 1D:
$250.37
$258.21
Intervallo di 1 settimana:
$245.00
$259.03
Portata 52W:
$110.00
$259.03
Ligand Pharmaceuticals Inc Stock (LGND) Company Profile
Nome
Ligand Pharmaceuticals Inc
Settore
Industria
Telefono
858-550-7500
Indirizzo
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
Compare LGND vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LGND
Ligand Pharmaceuticals Inc
|
255.25 | 5.08B | 274.48M | 153.56M | 114.06M | 7.3755 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-11 | Iniziato | BofA Securities | Buy |
| 2025-12-09 | Iniziato | Citigroup | Buy |
| 2025-04-10 | Iniziato | Stifel | Buy |
| 2024-10-03 | Iniziato | Oppenheimer | Outperform |
| 2024-07-30 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-04-14 | Ripresa | Stephens | Overweight |
| 2021-02-04 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-06 | Iniziato | Barclays | Overweight |
| 2020-03-24 | Downgrade | Argus | Buy → Hold |
| 2020-03-10 | Iniziato | Guggenheim | Neutral |
| 2020-02-06 | Iniziato | The Benchmark Company | Buy |
| 2019-09-19 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-06-11 | Iniziato | Barclays | Equal Weight |
| 2019-05-03 | Reiterato | H.C. Wainwright | Buy |
| 2019-03-06 | Reiterato | H.C. Wainwright | Buy |
| 2018-10-29 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2018-10-02 | Reiterato | H.C. Wainwright | Buy |
| 2018-09-11 | Reiterato | Argus | Buy |
| 2018-08-17 | Iniziato | Goldman | Neutral |
| 2018-08-08 | Downgrade | ROTH Capital | Buy → Neutral |
| 2018-06-21 | Iniziato | Argus | Buy |
| 2017-12-27 | Reiterato | H.C. Wainwright | Buy |
| 2017-09-05 | Ripresa | H.C. Wainwright | Buy |
| 2016-10-05 | Reiterato | H.C. Wainwright | Buy |
| 2016-08-05 | Downgrade | Deutsche Bank | Hold → Sell |
| 2016-03-11 | Iniziato | Sidoti | Buy |
| 2016-03-03 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Ligand Pharmaceuticals Inc Borsa (LGND) Ultime notizie
Ligand Pharmaceuticals director Jason Haas sells $1.65m stock By Investing.com - Investing.com South Africa
Ligand (LGND) director exercises options, sells 6,461 common shares around $255–$256 - Stock Titan
Kozarich Sells Shares of Ligand Pharmaceuticals - Intellectia AI
Ligand Pharmaceuticals Director Unloads 2,501 Shares — Should You Be Concerned? - Yahoo Finance
TVTX, LGND Stocks In Spotlight Ahead Of Monday’s FDA Call On Kidney Drug Filspari - Stocktwits
Ligand Pharmaceuticals Stock 9-Day Winning Spree: Stock Climbs 11% - Trefis
Ligand Pharmaceuticals Stock Rockets 11% With 9-Day Winning Streak - Trefis
Insider Sell: John Lamattina Sells Shares of Ligand Pharmaceuticals Inc (LGND) - GuruFocus
Ligand Pharma director John L. LaMattina sells $1.15 million stock - Investing.com
Ligand Pharmaceuticals director Jason Aryeh sells $1.25m in stock By Investing.com - Investing.com India
Ligand Pharmaceuticals director Jason Aryeh sells $1.25m in stock - Investing.com UK
Ligand Pharmaceuticals Director Sold Shares Worth Over $1.1M - TradingView
Director-linked funds trim Ligand (LGND) stake with 5,000-share sale - Stock Titan
Director sells 4,591 Ligand (LGND) shares in multiple open-market trades - Stock Titan
LGND (NASDAQ) Form 144 shows 4,000-share option exercise and restricted stock notices - Stock Titan
XOMA Royalty Corporation Declares Quarterly Preferred Stock Dividend and Announces Redemption of Its Perpetual Preferred Stock and CVR Dividend Record Date - Benzinga
JALAA Equities LP sells 500 Ligand (LGND) shares; 4,500 linked to Wells Fargo - Stock Titan
Ligand Pharmaceuticals Incorporated $LGND Shares Purchased by GW&K Investment Management LLC - MarketBeat
Franklin Resources Inc. Acquires 266,304 Shares of Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Ligand Pharmaceuticals stock hits 52-week high at $254.46 By Investing.com - Investing.com Nigeria
[144] LIGAND PHARMACEUTICALS INC SEC Filing - Stock Titan
Ligand Pharmaceuticals stock hits 52-week high at $254.46 - Investing.com
Ligand Pharmaceuticals to hold Investor Day in NYC on Dec 8, 2026, sharing strategy and financial outlook. - Pluang
Ligand Announces 2026 Investor Day in New York City - The Manila Times
Los Angeles Capital Management LLC Boosts Stake in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
BNP Paribas Financial Markets Buys 30,865 Shares of Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
LGND (LGND) director receives RSUs, stock options and tax-withholding share disposition - Stock Titan
Ligand Pharmaceuticals (LGND) director awarded RSUs and options in new equity grants - Stock Titan
Director John L. Lamattina receives LGND (LGND) RSUs and stock options - Stock Titan
Ligand (LGND) director John Kozarich receives RSUs and stock options grant - Stock Titan
Ligand (NASDAQ: LGND) director Jason Haas receives RSU and option grants - Stock Titan
Ligand (LGND) director Nancy Ryan Gray receives new RSUs and options - Stock Titan
Ligand Pharma Shareholders Back Governance and Incentive Plan - TipRanks
Ligand (NASDAQ: LGND) investors approve board slate, auditor and stock plan - Stock Titan
A Ligand Pharmaceuticals (LGND) Insider Sold 5,000 Shares for $1.1 Million - AOL.com
Cibc World Market Inc. Has $4.85 Million Holdings in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Bank of America Securities Remains a Buy on Ligand Pharma (LGND) - The Globe and Mail
Ligand Pharmaceuticals Insider Sold Shares Worth $1,135,316, According to a Recent SEC Filing - Moomoo
Ligand Pharmaceuticals CLO Reardon sells $1.1 million in stock By Investing.com - Investing.com Australia
Ligand Pharmaceuticals CLO Reardon sells $1.1 million in stock - Investing.com
Ligand (NASDAQ: LGND) CLO sells 5,000 shares, exercises options - Stock Titan
Ligand Shares Hold Up in Biotech Rout While XOMA Deal Heads for Investor Vote - Bez Kabli
Levi & Korsinsky LLP, National Class Action Law Firm, Announces Class Action Investigation Against Robinhood and Other Brokers on Behalf of Investors in Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) - TMX Newsfile
Legend Bio rises after early-stage data for in vivo CAR-T therapy - Seeking Alpha
How The Ligand Pharmaceuticals (LGND) Investment Story Is Evolving Without Fresh Analyst Targets - Yahoo Finance
Free float of Ligand Pharmaceuticals Incorporated – OTC:LGNDZ - TradingView
Number of shareholders of Ligand Pharmaceuticals Incorporated – OTC:LGNDZ - TradingView
Future Fund LLC Purchases Shares of 9,280 Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Insider Unloading: Octavio Espinoza Sells Options, Realizes $307K - Benzinga
Ligand Pharma (LGND) Receives a Buy from Bank of America Securities - The Globe and Mail
Ligand (NASDAQ: LGND) CFO exercises 1,736 stock options, now holds 27,679 shares - Stock Titan
Ligand Pharmaceuticals Inc Azioni (LGND) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Ligand Pharmaceuticals Inc Azioni (LGND) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Haas Jason | Director |
Jun 12 '26 |
Sale |
255.58 |
6,461 |
1,651,320 |
4,981 |
| Aryeh Jason | Director |
Jun 11 '26 |
Sale |
250.00 |
4,500 |
1,125,000 |
102,580 |
| Aryeh Jason | Director |
Jun 10 '26 |
Sale |
250.00 |
500 |
125,000 |
107,080 |
| LAMATTINA JOHN L | Director |
Jun 10 '26 |
Sale |
250.88 |
4,591 |
1,151,774 |
26,969 |
1.27%
1.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):